Alexander A. Seelenberger - 11 Aug 2023 Form 4 Insider Report for Vincerx Pharma, Inc. (VINC)

Reporting relationship: Officer
Issuer ticker: VINC
Reported as of: 11 Aug 2023
Net transaction value: +$9,968
SEC form: 4
Accepted by SEC: 14 Aug 2023, 16:09:28 UTC
Prior SEC filing: 16 Feb 2023
Next SEC filing: 08 Mar 2024
Source filing: View source filing
Reporting owner signature: By :/s/ Alexander A. Seelenberger

Key filing fact

Alexander A. Seelenberger filed Form 4 for Vincerx Pharma, Inc. (VINC) on 14 Aug 2023.

Key facts

This page summarizes Alexander A. Seelenberger's Form 4 filing for Vincerx Pharma, Inc. (VINC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Aug 2023, 16:09.

Change

Previous filing in this sequence was filed on 16 Feb 2023.
Current net transaction value: +$9,968.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VINC transaction

Common Stock

Purchase

Transaction value: $9,968
Shares: +10,500
Change %: +53%
Price: $0.9493
Shares after: 30,280
Date: 11 Aug 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a weighted average purchase price. Actual purchase prices ranged from $0.9374 to $0.9499 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.

Footnote F2

Includes 2,287 shares and 5,000 shares of common stock acquired on May 13, 2022 and May 12, 2023, respectively, under the Vincerx Pharma, Inc. 2021 Employee Stock Purchase Plan.